TY - JOUR AU - MR Litzow, AU - S Lee, AU - JM Bennett, AU - GW Dewald, AU - RE Gallagher, AU - V Jain, AU - EM Paietta, AU - J Racevskis, AU - Rousey, AU - JJ Mazza, AU - MS Tallman, PY - 2006/08/01 Y2 - 2024/03/28 TI - A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia JF - Haematologica JA - haematol VL - 91 IS - 8 SE - Clinical Trial, Phase II DO - 10.3324/%x UR - https://haematologica.org/article/view/4100 SP - 1105-1108 AB - We designed a phase II trial of arsenic trioxide (AT) for the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL). The dose administered was 0.25 mg/kg/day intravenously for 5-7 days per week for up to 60 days. Of 11 patients eligible, eight had B-cell and three T-cell ALL and two were Philadelphia chromosome-positive. The median duration of therapy was 21 days (range 7-28). One patient died of an infection. There were no responses. Ten patients have died. The median survival was 3.2 months (range 1.2-4.1). We conclude that AT is not active in the treatment of ALL. ER -